| P50 | author | Julie Jacobs | Q59662550 |
| | Evelien Smits | Q57385560 |
| | Filip Lardon | Q38324438 |
| P2093 | author name string | Patrick Pauwels | |
| | Vanessa Deschoolmeester | |
| P2860 | cites work | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 |
| | Infiltration of CD40-positive tumor-associated macrophages indicates a favorable prognosis in colorectal cancer patients | Q57709907 |
| | Effects of loss of p53 and p16 function on life span and survival of human urothelial cells | Q61791495 |
| | Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer | Q62528219 |
| | The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma | Q73434454 |
| | Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells | Q80178365 |
| | Determination of the activity of CD134 (OX-40) and CD137 (4-1BB) adhesive molecules by means of flow cytometry in patients with colorectal cancer metastases to the liver | Q82940240 |
| | Expression of CD137 and CD137 ligand in colorectal cancer patients | Q83093777 |
| | Assessment of activity of an adhesion molecule CD134 and CD137 in colorectal cancer patients | Q83462712 |
| | Programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with colon cancer | Q84794316 |
| | Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: their relationship to KRAS mutational status and disease recurrence | Q84872353 |
| | Colorectal Cancer Biomarkers: Where Are We Now? | Q27003134 |
| | Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models | Q27012618 |
| | 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity | Q27012963 |
| | Tumor stroma as targets for cancer therapy | Q27015980 |
| | The blockade of immune checkpoints in cancer immunotherapy | Q27860852 |
| | Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 |
| | Type, density, and location of immune cells within human colorectal tumors predict clinical outcome | Q28131662 |
| | The B7 family revisited | Q28240070 |
| | PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 |
| | The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity | Q28281686 |
| | Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells | Q28289781 |
| | Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates | Q29620051 |
| | IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity | Q29620119 |
| | Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer | Q33389767 |
| | Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients | Q33552813 |
| | Targeting CD137 enhances the efficacy of cetuximab. | Q33872482 |
| | LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites | Q34112310 |
| | Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75 | Q34122802 |
| | Accumulation of CCR4⁺CTLA-4 FOXP3⁺CD25(hi) regulatory T cells in colon adenocarcinomas correlate to reduced activation of conventional T cells | Q34154623 |
| | 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy | Q34180031 |
| | PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. | Q34283708 |
| | A Randomized Trial ofEx vivoCD40L Activation of a Dendritic Cell Vaccine in Colorectal Cancer Patients: Tumor-Specific Immune Responses Are Associated with Improved Survival | Q34365990 |
| | OX40 is a potent immune-stimulating target in late-stage cancer patients | Q34381674 |
| | GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability | Q34397451 |
| | Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma | Q34646279 |
| | Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. | Q34891171 |
| | The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints | Q34943776 |
| | The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy | Q34970884 |
| | Association between CTLA-4 rs231775 polymorphism and risk of colorectal cancer: a meta analysis | Q35173555 |
| | A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy | Q35584153 |
| | The association of CTLA-4 A49G polymorphism with colorectal cancer risk in a Chinese Han population. | Q53613411 |
| | Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). | Q53669679 |
| | Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. | Q54269172 |
| | Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma | Q57092257 |
| | Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. | Q38440279 |
| | CD40 expression in prostate cancer: a potential diagnostic and therapeutic molecule | Q38446133 |
| | Harnessing the Therapeutic Potential of Th17 Cells | Q38535119 |
| | CD70: An emerging target in cancer immunotherapy | Q38554834 |
| | FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer | Q39110395 |
| | CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth | Q39342390 |
| | Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. | Q39705105 |
| | An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy | Q39833507 |
| | CD40-mediated death and cytokine secretion in colorectal cancer: a potential target for inflammatory tumour cell killing | Q40126714 |
| | Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17‐1A | Q40589131 |
| | Association between cytotoxic T-lymphocyte antigen-4 +49A/G polymorphism and colorectal cancer risk: a meta-analysis. | Q41044394 |
| | CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts | Q41046616 |
| | Association between co-inhibitory molecule gene tagging single nucleotide polymorphisms and the risk of colorectal cancer in Chinese | Q41554593 |
| | Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma | Q41773434 |
| | CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies | Q41808416 |
| | Macrophages: Good guys in colorectal cancer | Q41868207 |
| | Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity | Q41983238 |
| | CD169-positive macrophages in regional lymph nodes are associated with a favorable prognosis in patients with colorectal carcinoma. | Q43899944 |
| | Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth | Q44124623 |
| | Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer | Q44175989 |
| | The effect of immune microenvironment on the progression and prognosis of colorectal cancer | Q44585249 |
| | Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation | Q45869327 |
| | Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis | Q47923806 |
| | Optimal delivery of colorectal cancer follow-up care: improving patient outcomes. | Q35654007 |
| | B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma | Q35813519 |
| | Thymus-derived regulatory T cells restrain pro-inflammatory Th1 responses by downregulating CD70 on dendritic cells | Q35819655 |
| | Programmed death ligand 2 in cancer-induced immune suppression. | Q35955151 |
| | Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer | Q35955354 |
| | Suppression of tumour-specific CD4⁺ T cells by regulatory T cells is associated with progression of human colorectal cancer | Q36073267 |
| | Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer | Q36299762 |
| | Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival | Q36402098 |
| | LAG-3 in Cancer Immunotherapy | Q36416383 |
| | Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody | Q36544926 |
| | Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors | Q36643696 |
| | Agonistic CD40 antibodies and cancer therapy | Q36664195 |
| | Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors. | Q36812982 |
| | Immunotherapy and immunoescape in colorectal cancer. | Q36996316 |
| | Upregulation of TIM-3 and PD-1 on CD4+ and CD8+ T Cells Associated with Dysfunction of Cell-Mediated Immunity after Colorectal Cancer Operation | Q37055901 |
| | Toward a molecular classification of colorectal cancer: the role of microsatellite instability status | Q37270176 |
| | Molecular mechanism and function of CD40/CD40L engagement in the immune system. | Q37474929 |
| | Highly prevalent colorectal cancer-infiltrating LAP⁺ Foxp3⁻ T cells exhibit more potent immunosuppressive activity than Foxp3⁺ regulatory T cells | Q37597429 |
| | Colorectal cancer and immunity: what we know and perspectives | Q37697520 |
| | Role of CD27/CD70 pathway of activation in immunity and tolerance | Q37779170 |
| | Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer | Q37930487 |
| | Cancer-associated fibroblasts as targets for immunotherapy | Q38063582 |
| | Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer | Q38207907 |
| | Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy | Q38214095 |
| | Th17 cells in cancer: the ultimate identity crisis. | Q38225542 |
| | Prognostic and predictive markers for the new immunotherapies. | Q38266704 |
| | The potential role of immunotherapy to treat colorectal cancer | Q38292169 |
| | The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? | Q38332778 |
| | PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy | Q38361400 |
| | OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. | Q38374889 |
| | Impact of the immune system and immunotherapy in colorectal cancer | Q38398877 |
| | Immuno-regulatory antibodies for the treatment of cancer | Q38424617 |
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal carcinoma | Q25493920 |
| | colorectal neoplasm | Q58833976 |
| | immune system phenomenon | Q64732757 |
| | checkpoint inhibitor | Q39086981 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 158038 | |
| P577 | publication date | 2015-10-29 | |
| P1433 | published in | Journal of Immunology Research | Q26841936 |
| P1476 | title | Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect | |
| P478 | volume | 2015 | |